348 related articles for article (PubMed ID: 38187386)
1. Current status and future challenges of CAR-T cell therapy for osteosarcoma.
Li S; Zhang H; Shang G
Front Immunol; 2023; 14():1290762. PubMed ID: 38187386
[TBL] [Abstract][Full Text] [Related]
2. CAR T targets and microenvironmental barriers of osteosarcoma.
Zhu J; Simayi N; Wan R; Huang W
Cytotherapy; 2022 Jun; 24(6):567-576. PubMed ID: 35193828
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).
Yu T; Jiang W; Wang Y; Zhou Y; Jiao J; Wu M
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38390935
[TBL] [Abstract][Full Text] [Related]
4. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
5. Treating osteosarcoma with CAR T cells.
Köksal H; Müller E; Inderberg EM; Bruland Ø; Wälchli S
Scand J Immunol; 2019 Mar; 89(3):e12741. PubMed ID: 30549299
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA
J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216
[TBL] [Abstract][Full Text] [Related]
7. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells.
Talbot LJ; Chabot A; Funk A; Nguyen P; Wagner J; Ross A; Tillman H; Davidoff A; Gottschalk S; DeRenzo C
Front Immunol; 2021; 12():691741. PubMed ID: 34211478
[TBL] [Abstract][Full Text] [Related]
8. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
Front Immunol; 2022; 13():887471. PubMed ID: 35935930
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
10. Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.
Nguyen DT; Liu R; Ogando-Rivas E; Pepe A; Pedro D; Qdaisat S; Nguyen NTY; Lavrador JM; Golde GR; Smolchek RA; Ligon J; Jin L; Tao H; Webber A; Phillpot S; Mitchell DA; Sayour EJ; Huang J; Castillo P; Gregory Sawyer W
Acta Biomater; 2023 Dec; 172():466-479. PubMed ID: 37788737
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
[TBL] [Abstract][Full Text] [Related]
12. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
13. Switchable CAR T cell strategy against osteosarcoma.
Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J
Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034
[TBL] [Abstract][Full Text] [Related]
14. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors.
Chen J; Jiang H
Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521
[TBL] [Abstract][Full Text] [Related]
15. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
Front Immunol; 2022; 13():927153. PubMed ID: 35757715
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy.
Liu Z; Zhou Z; Dang Q; Xu H; Lv J; Li H; Han X
Theranostics; 2022; 12(14):6273-6290. PubMed ID: 36168626
[TBL] [Abstract][Full Text] [Related]
17. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
Huang J; Huang X; Huang J
Front Immunol; 2022; 13():1019115. PubMed ID: 36248810
[TBL] [Abstract][Full Text] [Related]
18. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.
Zhang Q; Zhang Z; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Liu G; Tian X; Zhang Z
BMC Cancer; 2022 Nov; 22(1):1124. PubMed ID: 36320072
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
Aggeletopoulou I; Kalafateli M; Triantos C
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473878
[TBL] [Abstract][Full Text] [Related]
20. Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s.
DeRenzo C; Gottschalk S
Adv Exp Med Biol; 2020; 1257():109-131. PubMed ID: 32483735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
